AbbVie (ABBV) Gross Profit (2012 - 2026)

AbbVie (ABBV) has reported Gross Profit for 15 consecutive years, with $12.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Profit rose 14.64% year-over-year to $12.7 billion in Q2 2026; TTM through Jun 2026 was $46.0 billion, a 11.24% increase from a year earlier, with the FY2025 full-year figure at $43.0 billion, up 8.94% from the prior year.
• Gross Profit was $12.7 billion for Q2 2026 at AbbVie, up from $10.8 billion in the prior quarter.
• Over five years, Gross Profit peaked at $12.7 billion in Q2 2026 and troughed at $7.4 billion in Q3 2023.
• A 5-year average of $10.0 billion and a median of $10.3 billion in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit slipped 23.98% in 2023 and surged 37.7% in 2024, its largest moves.
• Over 5 years, Gross Profit stood at $11.0 billion in 2022, then dropped by 21.5% to $8.6 billion in 2023, then climbed by 24.53% to $10.7 billion in 2024, then rose by 12.7% to $12.1 billion in 2025, then advanced by 5.25% to $12.7 billion in 2026.
• The last three Gross Profit figures came in at $12.7 billion (Q2 2026), $10.8 billion (Q1 2026), and $12.1 billion (Q4 2025), per Business Quant data.